drugset / Trial / NCT05416359
Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
TQB3915 is a selective estrogen receptor covalent antagonist, by covalently binding to estrogen receptor, by changing the conformation of ERα, blocking intracellular signal transmission, thereby inhibiting the growth of tumor cells.
Timeline
- Start
- 2022-06
- Primary completion
- 2023-06
- Completion
- 2024-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQB3915 | Unknown | 300 mg | Oral |
| Subject | TQB3915 | Unknown | 450 mg | Oral |
| Subject | TQB3915 | Unknown | 600 mg | Oral |
| Subject | TQB3915 | Unknown | 750 mg | Oral |
| Subject | TQB3915 | Unknown | 900 mg | Oral |